Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership

Fineline Cube Dec 29, 2025
Company Deals

Shionogi Acquires RADICAVA ALS Business for $2.5 Billion from Tanabe Pharma

Fineline Cube Dec 23, 2025
Company Deals

Coherent Biopharma Licenses PDC CBP-1018 to MultiValent in $2 Billion Prostate Cancer Deal

Fineline Cube Dec 23, 2025
Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Policy / Regulatory

NDRC Expands Foreign Investment in Healthcare with 2025 Catalogue

Fineline Cube Dec 29, 2025
Company Drug

Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug

Fineline Cube Dec 29, 2025
Company Drug

Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency

Fineline Cube Dec 29, 2025
Drug

Hybio Pharmaceutical’s Liraglutide Filing Accepted by NMPA, Becomes Domestic Leader in GLP-1 Analog

Fineline Cube Jul 29, 2022

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced that its market filing for liraglutide, a...

Drug

Roche’s Rozlytrek Wins NMPA Approval for NTRK Fusion Gene-Positive Tumors

Fineline Cube Jul 29, 2022

Swiss pharmaceutical giant Roche announced that it has received marketing approval from the National Medical...

Company Drug

Kira Pharmaceuticals’ KP104 Receives Orphan Drug Designation for PNH Treatment

Fineline Cube Jul 29, 2022

Sino-US biotech Kira Pharmaceuticals announced that it has received an Orphan Drug Designation (ODD) from...

Policy / Regulatory R&D

Shenzhen Unveils Measures to Boost Biomedical and Medical Device Industries

Fineline Cube Jul 29, 2022

Shenzhen’s municipal Development and Reform Commission has released a series of measures to promote the...

Company

Merck’s Q2 Sales Surge 31% to USD 14.6B, Led by Keytruda and China Growth

Fineline Cube Jul 29, 2022

US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) reported Q2 2022 global sales of USD...

Company Drug

Takeda’s Alunbrig Prescribed in China for ALK+ NSCLC Treatment

Fineline Cube Jul 29, 2022

Japan-based Takeda Pharmaceutical Co., Ltd (TYO: 4502) announced that its lung cancer therapy Alunbrig (brigatinib)...

Company Deals

Cosmo Pharma’s Winlevi Cream Secures Greater China Licensing Deal with 3SBio

Fineline Cube Jul 29, 2022

Ireland-based Cosmo Pharmaceuticals NV (SWX: COPN) and China’s 3SBio Inc. (HKG: 1530) have signed a...

Company R&D

PerkinElmer and SCUT Launch Joint Translational Medicine Center

Fineline Cube Jul 29, 2022

US-based PerkinElmer and China’s South China University of Technology (SCUT) have officially launched their joint...

Policy / Regulatory

Sun Pharma’s Bicalutamide Supply Suspended in Multiple Chinese Regions

Fineline Cube Jul 28, 2022

India-based Sun Pharma has suspended the supply of its bicalutamide to Beijing, Tianjin, Jilin, Shanghai,...

Company Drug

MabPharm’s CMAB015 Biosimilar Receives NMPA Approval for Clinical Study

Fineline Cube Jul 28, 2022

Taizhou-based monoclonal antibody (mAb) biosimilars specialist MabPharm Ltd (HKG: 2181) announced that it has received...

Company Deals

CSPC Jushi Biopharm’s SYSA1801 ADC Secures Licensing Deal with Elevation Oncology

Fineline Cube Jul 28, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its subsidiary, CSPC Jushi Biopharmaceutical Co.,...

Policy / Regulatory

CDE Releases 61st Batch of Generic Reference Preparations, 34 New Specs Added

Fineline Cube Jul 28, 2022

The Center for Drug Evaluation (CDE) has released the 61st batch of chemical generic reference...

Company

Immunochina Pharmaceuticals Secures CAR-T Production License in Beijing

Fineline Cube Jul 28, 2022

Beijing-based Immunochina Pharmaceuticals has obtained a Drug Production License for its chimeric antigen receptor (CAR)...

Company Deals

Kolo Medical Raises RMB 100M in Series B2 to Launch High-Frequency Ultrasound Imaging System

Fineline Cube Jul 28, 2022

Suzhou-based Kolo Medical Inc., a leader in next-generation semiconductor ultrasound CMUT (Capacitive Micromachined Ultrasonic Transducer)...

Company Drug

Nestle Launches China’s First Cancer-Focused FSMP Product Oral Impact Su Yi Su

Fineline Cube Jul 28, 2022

Switzerland-based Nestle announced the launch of China’s first “foods for special medical purposes” (FSMP) product...

Company Digital

Sanofi’s Hornstein Sees China’s Online Hospitals Boosting Digital Health Strategy

Fineline Cube Jul 28, 2022

Sanofi’s outgoing China market president, Pius Hornstein, expressed confidence in the potential of China’s online...

Company Drug

Nuance Pharma Initiates Phase I Study for Ketorolac IV Infusion (NTM-001)

Fineline Cube Jul 27, 2022

China-based Nuance Pharma announced the initiation of subject enrollment and the first drug infusion in...

Company Drug

Henlius Biotech’s HanBeiTai Biosimilar of Avastin Accepted for CDE Review

Fineline Cube Jul 27, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) announced that the Center for Drug Evaluation (CDE) has...

Company Deals

CStone Pharmaceuticals and Kindstar Global Partner on Blood Tumor Precision Diagnosis and Treatment

Fineline Cube Jul 27, 2022

China-based CStone Pharmaceuticals (HKG: 2616) announced a strategic collaboration with compatriot firm Kindstar Global (HKG:...

Company Deals

Wanbangde Pharmaceutical to Acquire Consun Pharma Shares in RMB 2.2B Deal

Fineline Cube Jul 27, 2022

China-based Wanbangde Pharmaceutical Group has entered into a non-legally binding letter of intent with Consun...

Posts pagination

1 … 579 580 581 … 601

Recent updates

  • UniPath Bronchoscopic Robot Wins NMPA Approval, Expanding MedBot’s Surgical Portfolio
  • Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug
  • Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency
  • J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC
  • Hybio Pharmaceutical, Dr. Reddy’s Forge Peptide API Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

UniPath Bronchoscopic Robot Wins NMPA Approval, Expanding MedBot’s Surgical Portfolio

Company Drug

Livzon’s Lecankitug Accepted by NMPA as First Domestic Dual IL‑17A/F Psoriasis Drug

Company Drug

Novo Nordisk’s Sogroya Wins NMPA Approval for Pediatric Growth Hormone Deficiency

Company Drug

J&J’s Amivantamab Subcutaneous Wins China Approval for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.